MedPath

CIPLA USA INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

118

FDA:118

Drug Approvals

GABAPENTIN

Approval Date
May 1, 2025
FDA

grisofulvin

Approval Date
Mar 27, 2024
FDA

Sertraline Hydrochloride

Approval Date
Mar 8, 2024
FDA

Tenofovir disoproxil fumarate

Approval Date
Mar 6, 2024
FDA

Darunavir 600 and 800 mg

Approval Date
Jan 18, 2024
FDA

Testosterone Cypionate

Approval Date
Jan 17, 2024
FDA

ISOPROTERENOL

Approval Date
Jan 14, 2024
FDA

Dihydroergotamine Mesylate Nasal

Approval Date
Jan 13, 2024
FDA

Ipratropium Bromide and Albuterol Sulfate

Approval Date
Jan 11, 2024
FDA

Phytonadione

Approval Date
Jan 11, 2024
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 12
  • Next

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Plazomicin Study in ESRD Patients Receiving IHD

Phase 1
Completed
Conditions
End Stage Renal Disease
Interventions
First Posted Date
2021-01-07
Last Posted Date
2022-03-09
Lead Sponsor
Cipla USA Inc.
Target Recruit Count
6
Registration Number
NCT04699656
Locations
🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath